| Title: |
Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine |
| Authors: |
Ludovica Ferrari; Mirko Compagno; Laura Campogiani; Elisabetta Teti; Tiziana Mulas; Davide Checchi; Grazia Alessio; Federica Caldara; Luigi Coppola; Giuseppe De Simone; Laura Ceccarelli; Ilaria Spalliera; Pietro Vitale; Sandro Grelli; Massimo Andreoni; Loredana Sarmati; Marco Iannetta |
| Source: |
Vaccines, Vol 10, Iss 1238, p 1238 (2022) |
| Publisher Information: |
MDPI AG |
| Publication Year: |
2022 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
vaccines; SARS-CoV-2; COVID-19; healthcare workers; BNT162b2; side effects; Medicine |
| Description: |
Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side effects and performed a nested case–control analysis comparing plasma levels of specific IgG titers between SARS-CoV-2-naïve and previously infected subjects after the first and the second vaccine doses. Results: After the first dose, SARS-CoV-2-naïve subjects experienced side effects more often than SARS-CoV-2 naïve subjects. Individuals with prior SARS-CoV-2 infection more often reported pain at the injection site, weakness, and fever than SARS-CoV-2-naïve subjects. After the second dose, the frequency of side effects was similar in the two groups. All subjects with prior SARS-CoV-2 infection developed either a high (>100 AU/mL) or intermediate (10–100 AU/mL) antibody titer. Among SARS-CoV-2-naïve subjects, the majority developed an intermediate titer. After the second dose, a high (>2000 AU/mL) antibody titer was more common among subjects with prior SARS-CoV-2 infection. Conclusions: vaccine-related side effects and a higher anti-SARS-CoV-2-RBD IgG titer were more common in subjects with previous infection than in SARS-CoV-2-naïve after the first, but not after the second dose of the BNT162b2 vaccine. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://www.mdpi.com/2076-393X/10/8/1238; https://doaj.org/toc/2076-393X; https://doaj.org/article/1095e62963ea44edbe361b2823a9f243 |
| DOI: |
10.3390/vaccines10081238 |
| Availability: |
https://doi.org/10.3390/vaccines10081238; https://doaj.org/article/1095e62963ea44edbe361b2823a9f243 |
| Accession Number: |
edsbas.158D8170 |
| Database: |
BASE |